Geron Corporation (NASDAQ:WITH TASTE) is one of the the best fast-growing penny stocks to buy according to analysts. On Jan. 29, TD Cowen analyst Tara Bancroft cut the firm’s price target on Geron to $3 from $4 while maintaining a buy rating. This adjustment followed an update to the company’s financial model in anticipation of Q4 2025 results.

In the third quarter of 2025, Geron Corporation (NASDAQ: GERN ) expanded its reach by adding 150 new order accounts, a sequential increase of 15%, and successfully initiated its first shipment of RYTELO to Germany under an early access program. In addition, Geron’s clinical pipeline remains on track, with its Phase 3 trial for relapsed/refractory myelofibrosis fully enrolled and an interim analysis expected in the second half of 2026.

Despite these gains, demand for RYTELO experienced a 3% decline compared to the prior quarter as new patient growth was offset by discontinuations of back-line therapies. To address these headwinds, Geron implemented a restructuring and provided financial guidance for 2026 with a projection of $220 million to $240 million in RYTELO revenue, with a focus on profitability and a strengthened commercial footprint.

Geron Corporation (NASDAQ: GERN ) is a commercial-stage biopharmaceutical company developing therapeutic products for oncology.

While we recognize GERN’s potential as an investment, we believe some AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: 30 stocks that should double in 3 years i 11 Hidden AI Stocks to Buy Right Now.

Disclosure: no. This article is originally published in Monkey Insider.